Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Metadata
Title
Arg and DAP3 expression was correlated with human thymoma stage
Authors
Hidefumi Sasaki
Nobuyuki Ide
Haruhiro Yukiue
Yoshihiro Kobayashi
Ichiro Fukai
Yosuke Yamakawa
Yoshitaka Fujii
Publication date
01-11-2004
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 6/2004
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-004-2153-3

Other articles of this Issue 6/2004

Clinical & Experimental Metastasis 6/2004 Go to the issue

OriginalPaper

Collagen type IV, laminin, α-smooth muscle actin (αSMA), α1 and α6 integrins expression in the liver with metastases from malignant gastrointestinal tumours

OriginalPaper

Breast adenocarcinoma cell adhesion to the vascular subendothelium in whole blood and under flow conditions: Effects of α v β 3 and α IIb β 3 antagonists

OriginalPaper

Osteopontin regulates multiple functions contributing to human colon cancer development and progression

OriginalPaper

Breast cancer cells with inhibition of p38α have decreased MMP-9 activity and exhibit decreased bone metastasis in mice

OriginalPaper

Common origins of MDA-MB-435 cells from various sources with those shown to have melonoma properties

OriginalPaper

SGK1, a potential regulator of c-fms related breast cancer aggressiveness
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits